News|Articles|March 6, 2024
CT-Based Staging System for Coronary Artery Disease Gets FDA's Breakthrough Device Designation
Author(s)Jeff Hall
Employing quantitative computed tomography, the staging system’s insights on stenosis, ischemia and coronary atherosclerosis may facilitate individualized assessments of heart disease risk.
Advertisement
The Food and Drug Administration (FDA) has granted Breakthrough Device Designation for Cleerly’s Coronary Artery Disease (CAD) Staging System.
Offering a four-stage approach that incorporates total plaque volume (TPV) and percent atheroma volume (PAV) assessments from quantitative computed tomography (CT), Cleerly said the
Emphasizing the system’s potential for providing individual risk assessments for heart disease, Cleerly added that a randomized controlled trial (TRANSFORM) will assess use of the CAD Staging System for patients with diabetes, pre-diabetes or metabolic syndrome who are currently asymptomatic for heart disease.
“As our Cleerly CAD Staging System becomes available to physicians and patients, it will provide the rationale for preventive tailored treatment of CAD with risk-based therapy goals,” said Udo Hoffmann, M.D., M.P.H., the chief scientific officer of Cleerly.
Advertisement
Related to this article
Catch up on the top radiology content of the past week.
In the second of a two-part interview, Kalpana Kanal, PhD, and Mahadevappa Mahesh, MS, PhD, FAPPM, FACR, discussed future directions for research on CT radiation dosing, including the potential of indication-specific diagnostic reference levels (DRLs).
Catch up on the latest imaging research from the recent European Society of Cardiology (ESC) Congress.
In the first of a two-part interview, Kalpana Kanal, PhD, and Mahadevappa Mahesh, MS, PhD, FAPPM, FACR, discussed recently published research showing significant declines in computed tomography (CT) radiation dosing over the past decade.
A new study shows that even small plaque volume may be associated with significantly higher risk for cardiovascular events, making the enhanced spatial resolution available with advanced imaging even more critical in risk stratification.
New research presented at the European Society of Cardiology (ESC) conference demonstrates that fractional flow reserve (FFR) based off CCTA exams significantly decreases unnecessary invasive coronary angiography (ICA) procedures for patients with stable chest pain and obstructive stenosis.
Newly cleared findings for the adjunctive AI platform a2z-Abdo-Triage include acute appendicitis, renal traumatic injury, ureteral stone and retroperitoneal hematoma.
Emerging research demonstrates the increasing stability of attenuation on clinically relevant VMIs with photon-counting CT and a redefined role of kV that may have implications for longitudinal quantitative CT.
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
FDA Clears AI-Powered Triage Software for 10 Findings on Abdominopelvic CT
2
FDA Grants Final Approval of Emerging Radiopharmaceutical for GEP-NET Treatment
3
Can MRI-Derived Tumor Habitat Subregions Bolster Recurrence Risk Stratification in Stage 2 and 3 Breast Cancer Cases?
4
Is Private Practice Radiology as Important as an Amusement Park?
5